Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LDN-071
- Development stage
- Preclinical
- Lead developer
- Ladon Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LDN-071 is a novel, first-in-class, targeted oral therapy developed by Ladon Therapeutics for the treatment of inflammatory bowel disease (IBD). It is designed using the A3SMO platform to act locally in the gastrointestinal tract and is resistant to enzymatic digestion. The drug aims to provide local immunosuppression, overcoming resistance to biological therapies and reducing intestinal inflammation. LDN-071 represents a new molecular entity with a unique mechanism focused on localized action within the gut.
02
Targets
PAI-1 (Plasminogen activator inhibitor type 1)
Beyond the preview
Go deeper on LDN-071.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LDN-071.